Skip to main content
KWANGDONG PHARMACEUTICAL CO.,LTD logo

KWANGDONG PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 009290 ISIN · KR7009290008 KO Manufacturing
Open in API
Filings indexed 280 across all filing types
Latest filing 2026-03-09 Director's Dealing
Country KR South Korea
Listing KO 009290

About KWANGDONG PHARMACEUTICAL CO.,LTD

https://eng.ekdp.com/

Kwangdong Pharmaceutical is a human healthcare company that develops, manufactures, and sells a diverse range of products, including pharmaceuticals and health-oriented beverages. Founded on the principle of the 'scientification of Oriental medicine,' the company integrates traditional Korean medicinal concepts with modern Western science. Its portfolio includes Over-the-Counter (OTC) and prescription (ETC) drugs, general health supplements, and traditional health foods. The company is also prominent in the consumer market with its popular beverage lines, featuring well-known products such as the Vita 500 vitamin drink and Corn Silk Tea. Additionally, Kwangdong is involved in the distribution of mineral water.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share ownership changes of a specific executive (Park Sang-young) at Kwangdong Pharmaceutical. This type of filing is a standard regulatory requirement for insider trading or changes in executive shareholdings, which corresponds to the 'Director's Dealing' category.
2026-03-09 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service in Korea. This type of filing is a standard regulatory disclosure for insider transactions or changes in share ownership by company directors/executives. According to the provided definitions, reports of personal share transactions by company directors and executives are classified as 'Director's Dealing' (DIRS).
2026-03-09 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (often referred to as a Proxy Solicitation Statement). It contains information regarding the upcoming Annual General Meeting (AGM), including the agenda, proxy solicitation details, and financial statements for the preceding fiscal year. This document is specifically designed to solicit votes from shareholders for the AGM, fitting the definition of a Proxy Solicitation & Information Statement (PSI).
2026-02-27 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Kwangdong Pharmaceutical. It contains the agenda for the 53rd Annual General Meeting, including financial statement approval, board changes, and director remuneration. While it contains financial data, it is primarily a proxy statement/notice for shareholders to attend the meeting and vote, which falls under the Proxy Solicitation & Information Statement category.
2026-02-25 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Kwangdong Pharmaceutical. It outlines the date, location, and specific agenda items for the upcoming Annual General Meeting, including the approval of financial statements, amendments to the articles of incorporation, and the appointment of directors. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the meeting and the matters to be voted upon.
2026-02-23 Korean
기타경영사항(자율공시)
AGM Information Classification · 95% confidence The document is a short regulatory disclosure (자율공시) from Kwangdong Pharmaceutical regarding the adoption of an electronic voting system for their upcoming general meeting. It does not fit into specific categories like financial reports, M&A, or director dealings. As it is a general corporate governance announcement that does not fall into the other specialized categories, it is classified as a Regulatory Filing (RNS).
2026-02-23 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.